Allergan, Inc.: Another Billion-Dollar Buyout Target

Valeant might continue its acquisition streak with the hefty purchase of Allergan.

Max Macaluso
Max Macaluso and Michael Douglass
Apr 23, 2014 at 9:15AM
Health Care

Earlier this week, investors following the pharmaceutical industry may have been surprised to hear that Pfizer was interested in acquiring AstraZeneca. However, the billion-dollar buyout news didn't stop there.

Yesterday, shares of Allergan (UNKNOWN:AGN.DL), the company best-known for its key product Botox, popped more than 15% on news that Valeant Pharmaceuticals (NYSE:BHC) is keen on acquiring it. In the following video, analysts Max Macaluso and Michael Douglass discuss this potential deal, and its implications for investors.